![](https://media.springernature.com/w110h61/springer-static/image/art%3A10.1007%2Fs11239-024-02981-4/MediaObjects/11239_2024_2981_Fig1_HTML.png?as=webp)
Overview
Journal of Thrombosis and Thrombolysis is a resource for those involved in the treatment and clinical investigation of thrombotic disorders involving the cardiovascular and cerebrovascular systems.
- Focuses on pathobiology of thrombosis and vascular disorders and the use of anticoagulants, platelet antagonists, cell-based therapies and interventions in scientific investigation, clinical-translational research, population science and patient care.
- Publishes original work emphasizing the interface between fundamental scientific principles and clinical investigation and is a platform for translational research, drug development, clinical trials, new drugs and devices, and patient-directed applications.
- Seeks orignal manuscripts related to cardiovascular disease, laboratory investigation, pharmacogenetics, clinical research, global health, population science, and epidemiology and state-of-the-art reviews and position papers.
- Editor-in-Chief
-
- Diana Gorog
- Impact factor
- 4.0 (2022)
- 5 year impact factor
- 3.2 (2022)
- Submission to first decision (median)
- 20 days
- Downloads
- 516,913 (2023)
![](https://media.springernature.com/w90/springer-static/cover/journal/11239/57/4.jpg?as=webp)
Latest articles
Journal updates
-
Open Call- Focus Issue on “Novel Antithrombotic Medications”
Guest Editors:
Diana A Gorog, National Heart and Lung Institute, Imperial College, London, UK
Geoffrey D Barnes, University of Michigan Health, USA
Antithrombotic medications remain the cornerstone in the management of cardiovascular disease. While currently available medications greatly reduce ischemic and thromboembolic risk in a number of conditions, ranging from venous thromboembolism to coronary artery disease, myocardial infarction and stroke, these agents have limitations. These include a residual ischemic risk despite current optimal medications in some individuals, delayed onset of action in others, whilst yet others may experience bleeding complications. These factors contribute significantly to mortality and morbidity.
Currently, there are several novel antithrombotic medications on the horizon, undergoing clinical and/or laboratory evaluation. These include, among others, intravenous and subcutaneous antiplatelet medications, and novel anticoagulants including those targeting factor XI and factor XII.
We are launching a call for papers for a special themed issue of the Journal of Thrombosis and Thrombolysis on “Novel Antithrombotic Medications” to highlight research in this important emerging field. Submission may take the form of original research (clinical, translational or basic science), clinical trials, meta-analyses, or review articles.
Please indicate in a cover letter if your submission is targeted at this call.
Submit your manuscript here
Please see the submission guidelines here
Journal information
- Electronic ISSN
- 1573-742X
- Abstracted and indexed in
-
- BFI List
- Baidu
- CLOCKSS
- CNKI
- CNPIEC
- Chemical Abstracts Service (CAS)
- Current Contents/Clinical Medicine
- Dimensions
- EBSCO
- EMBASE
- Google Scholar
- INIS Atomindex
- Japanese Science and Technology Agency (JST)
- Medline
- Naver
- OCLC WorldCat Discovery Service
- Pathway Studio
- Portico
- ProQuest
- Reaxys
- SCImago
- SCOPUS
- Science Citation Index Expanded (SCIE)
- Semantic Scholar
- TD Net Discovery Service
- UGC-CARE List (India)
- Wanfang
- Copyright information
-
© Springer Science+Business Media, LLC, part of Springer Nature